Inmazeb use while Breastfeeding
Medically reviewed by Drugs.com. Last updated on Feb 4, 2024.
Inmazeb Levels and Effects while Breastfeeding
Summary of Use during Lactation
Inmazeb is a mixture of monoclonal antibodies, atoltivimab, maftivimab, and odesivimab that are directed against Zaire ebolavirus glycoprotein. No information is available on the use of Inmazeb during breastfeeding. Because Inmazeb is a mixture of large protein molecules with molecular weights of 144,000 to 146,000 Da, the amount in milk is likely to be very low and absorption is unlikely because the antibodies are probably destroyed in the infant's gastrointestinal tract. Until more data become available, Inmazeb should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant. The US Centers for Disease Control and Prevention recommend that patients with confirmed Zaire ebolavirus not breastfeed their infants to reduce the risk of postnatal transmission of Zaire ebolavirus infection.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Inmazeb
CAS Registry Number
2135632-29-8; 2135632-36-7; 2135632-30-1
Drug Class
Breast Feeding
Lactation
Milk, Human
Antibodies, Monoclonal
Antibodies, Viral
Antiviral Agents
-
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
- Drug Levels and Effects
- Substance Identification
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.